Prescient Therapeutics Limited (ASX:PTX) Annual Report 2020
The latest annual report of Prescient Therapeutics Limited (PTX) was published on 30 Jun 2020. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.
Key Statistics - PTX Annual Results
Amounts in AUD
PTX Income Statement 2020 Annual Report
As per the latest Income Statement of PTX, the Net revenue decreased by $-570.17K (-33%) compared to the previous period. The operating income in 2020 increased by - (-). The net income as per the annual report was $-3.32M which increased by $476.04K (13%) compared to previous year.
Income Statement Report (2020/2019)
| 2020 | 2019 | |
|---|---|---|
| Total Revenue | $1.15M | $1.72M |
| Gross Profit | $4.27M | $4.27M |
| Operating Income | - | - |
| Income Before Tax | - | - |
| Net Income | $-3.32M | $-3.80M |
Balance Sheet - PTX 2020 Annual Report
Read further: PTX Balance Sheet Detailed Analysis
The latest balance sheet from annual result of Prescient Therapeutics Limited showed the company increased the cash on balance sheet by $0.00 (0%). The Net tangible assets of PTX on the balance sheet were at $16.82M which is $0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.
Balance Sheet Statement Report (2020/2019)
| 2020 | 2019 | |
|---|---|---|
| Cash | $9.77M | $9.77M |
| Total Assets | - | - |
| Long Term Debt | - | - |
| Total Liabilities | $272.92K | $272.92K |
| Total Shareholder Equity | - | - |
| Net Tangible Assets | $16.82M | $16.82M |
Cash Flow Statement - PTX 2020 Annual Report
The 2020 annual cash flow statement of Prescient Therapeutics Limited showed that the net income increased by $476.04K (13%) compared to previous reporting period. Also the capital expenditure of PTX increased by - (-).
As of 2020, the total cash from investing activities was - and total cash from financing activities was -.
Cash Flow Statement Report (2020/2019)
| 2020 | 2019 | |
|---|---|---|
| Net Income | $-3.32M | $-3.80M |
| Capital Expenditures | - | - |
| Dividends Paid | - | - |
| Total Cash From From Investing Activities | - | - |
| Total Cash From From Financing Activities | - | - |
Prescient Therapeutics Limited Annual Report History
Income Statement
Income Statement history of Prescient Therapeutics Limited (ASX:PTX)
| 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2018 | 30 Jun 2017 | |
|---|---|---|---|---|
| Total Revenue | $1.15M | $1.72M | $1.06M | $1.22M |
| Cost Of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Research Development | - | - | - | - |
| Selling General Administrative | - | - | - | - |
| Non Recurring | - | - | - | - |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | - | - | - | - |
| Total Other Income Expense Net | - | - | - | - |
| Ebit | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | - | - | - | - |
| Income Before Tax | - | - | - | - |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Minority Interest | - | - | - | - |
| Net Income From Continuing Ops | - | - | - | - |
| Discontinued Operations | - | - | - | - |
| Extraordinary Items | - | - | - | - |
| Effect Of Accounting Charges | - | - | - | - |
| Other Items | - | - | - | - |
| Net Income | $-3.32M | $-3.80M | $-2.57M | $-2.57M |
| Net Income Applicable To Common Shares | - | - | - | - |
Balance Sheet Statement
Balance Sheet Statement history of Prescient Therapeutics Limited (ASX:PTX)
| 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2018 | 30 Jun 2017 | |
|---|---|---|---|---|
| Cash | $9.77M | $9.77M | - | - |
| Total Assets | - | - | - | - |
| Total Liab | $272.92K | $272.92K | - | - |
| Long Term Debt | - | - | - | - |
| Total Stockholder Equity | - | - | - | - |
| Net Tangible Assets | $16.82M | $16.82M | - | - |
Cash Flow Statement
Cash Flow Statement history of Prescient Therapeutics Limited (ASX:PTX)
| 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2018 | 30 Jun 2017 | |
|---|---|---|---|---|
| Net Income | $-3.32M | $-3.80M | - | - |
| Capital Expenditures | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Total Cashflows From Investing Activities | - | - | - | - |
| Total Cash From Financing Activities | - | - | - | - |